Matthew Strobeck, Director at Accelerate Diagnostics Inc. (NASDAQ:AXDX), bought 20,000 shares of Common Stock on Monday. The transaction was executed indirectly via the Birchview Fund, LLC (of which Strobeck is the CEO) and the insider paid a price of $16.70 per share. Following the director’s first stock trade of the fiscal year, he now owns a total of 2,065,560 company shares.
This quarter showed some very active insider trading at Accelerate Diagnostics. Jack Schuler, Director and large shareholder at the firm, purchased 20,000 shares of Common Stock in July, paying a price of $19.89 per share. The acquisition was completed merely two weeks after he had bought 8,698 shares of Common Stock for $25.70 per share.
Another shareholder at the $754.5 million market cap technology firm that has been purchasing large bulks of stock throughout July is Larry Feinberg. The insider purchased 10,000 shares of Common Stock paying $19.96 for each share, two days after he had acquired 10,000 shares for a price of $23.12 per share.